Operational Costs Compared: SG&A Analysis of AbbVie Inc. and United Therapeutics Corporation

SG&A Trends: AbbVie vs. United Therapeutics Over a Decade

__timestampAbbVie Inc.United Therapeutics Corporation
Wednesday, January 1, 20147724000000381287000
Thursday, January 1, 20156387000000452612000
Friday, January 1, 20165855000000316800000
Sunday, January 1, 20176275000000330100000
Monday, January 1, 20187399000000265800000
Tuesday, January 1, 20196942000000336200000
Wednesday, January 1, 202011299000000423900000
Friday, January 1, 202112349000000467000000
Saturday, January 1, 202215260000000487000000
Sunday, January 1, 202312872000000477100000
Monday, January 1, 202414752000000
Loading chart...

Unleashing the power of data

A Decade of SG&A: AbbVie vs. United Therapeutics

In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, AbbVie Inc. and United Therapeutics Corporation have showcased contrasting strategies in managing Selling, General, and Administrative (SG&A) expenses. AbbVie, a global biopharmaceutical leader, has seen its SG&A expenses grow by approximately 66% from 2014 to 2023, peaking in 2022. This reflects its aggressive expansion and investment in marketing and administrative capabilities. In contrast, United Therapeutics, a pioneer in biotechnology, maintained a more stable SG&A trajectory, with a modest increase of around 28% over the same period. This stability underscores its focused approach in niche markets. As the industry faces mounting pressures, these insights into SG&A management offer a glimpse into the strategic priorities of these pharmaceutical giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025